Bio-Techne (NASDAQ: TECH) reported Q1 EPS of $0.41, $0.02 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $276.9 million versus the consensus estimate of $287.66 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.